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Introduction: To improve prognosis and quality of lung cancer care 
the Danish Lung Cancer Group has developed a strategy consisting 
of national clinical guidelines and a clinical quality and research 
database. The first edition of our guidelines was published in 1998 
and our national lung cancer registry was opened for registrations in 
2000. This article describes methods and results obtained by multi-
disciplinary collaboration and illustrates how quality of lung cancer 
care can be improved by establishing and monitoring result and pro-
cess indicators.
Methods: A wide range of indicators was established, validated, and 
monitored. By registration of all lung cancer patients since the year 
2000, data on more than 40,000 patients have been included in the 
database. Results are reported periodically/quarterly and submitted 
to formal auditing on an annual basis.
Results: Improvements in all outcome indicators are documented 
and statistically significant. Thus the 1-year overall survival rate 
has increased between 2003 and 2011 from 36.6% to 42.7%, the 
2-year survival rate from 19.8% to 24.3%, and the 5-year survival 
rate from 9.8% to 12.1%. Five-year survival after surgical resec-
tion has increased from 39.5% to 48.1%. Improvements of waiting 
times, accordance between cTNM and pTNM, and resection rates 
are documented.
Conclusion: The Danish experience shows that a national quality 
management system including national guidelines, a database with 
high data quality, frequent reports, audit and commitment from all 
stakeholders can contribute to improve clinical practice, improve 
core results, and reduce regional differences.
Key Words: Lung Cancer, Quality of care, Quality, Indicators, 
Outcome measurement, Monitoring, Survival, Prognosis.
(J Thorac Oncol. 2013;8: 1238–1247)
The Danish Lung Cancer Group (DLCG) was established in 1991 including representatives from all contributing 
specialties. The initiative was a response to reports published 
in 1990s showing poor results of treatment and quality of 
care for lung cancer in Denmark. The relative 5-year survival 
had for several years shown no improvement, and the Danish 
results were significantly inferior compared with survival 
rates observed in Nordic countries.1–3 A fatalistic professional 
approach to the disease was dominant, and it was believed that 
the only way to reduce lung cancer overall mortality was to 
reduce the number of new cases through smoking cessation.4 
DLCG was initially formed as a voluntary group consisting of 
representatives from all medical specialties working with diag-
nosis or treatment of lung cancer, but in later years the multi-
disciplinary groups working with specific cancers like DLCG 
have been formally connected to the national health authori-
ties in a regulatory framework defining tasks and funding. As 
a result of the formal connection with the health authorities, 
reporting to the database also became mandatory. The primary 
goal of DLCG was to improve survival and the overall clinical 
management of Danish lung cancer patients. The primary task 
was first to obtain information regarding the clinical practices 
from 90 departments involved in diagnosing and treatment of 
lung cancer. The results demonstrated huge variations in the 
clinical management and it was therefore decided to prepare 
a national set of clinical recommendations of all aspects of 
the diagnostic and primary treatment processes including the 
handling of patients suspected for lung cancer in general prac-
tice. The first edition of nationwide guidelines was published 
in 1998, and the dual strategy was to implement the guide-
lines in clinical practice in the period 1998–2000, and there-
after monitor the adherence to the guidelines by reporting a 
complete set of data to a registry established by the DLCG. 
The Danish Lung Cancer Registry (DLCR) was opened for 
registration in 2000.The results from the registry have since 
continuously been passed on to the health professionals, the 
health authorities, and the public.
When DLCR was established, the national guidelines 
were used to identify clinical problems of interest for reg-
istration, and these elements together with information on 
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morbidity and prognostic factors formed the first set of data 
in the database. The establishment of DLCR did, however, 
coincide with the international trend for developing ways to 
improve and monitor quality of health care, which in Denmark 
among others was represented by the National Indicator 
Project, which was established in 2000, and in 2002 lung can-
cer as the only cancer disease became a part of this project.5 
The aims of the two organizations were largely overlapping, 
and DLCR recognized that the indicator-based model used by 
the National Indicator Project would increase the credibility 
of the results from the database and the cooperation would 
anchor DLCR in the managements system.
This article describes the methods used by DLCG and 
DLCR and the results obtained through this work and dis-
cusses how it is possible to improve the quality of lung cancer 
care through monitoring quality indicators.
MATERIALS AND METHODS
DLCG/DLCR has established, validated, and monitored 
a wide range of result and process indicators, and through 
careful nationwide registration of all lung cancer patients 
since the year 2000 to date (2013) a total of more than 45,000 
patients have been included in the database. Data describing 
waiting times, diagnostic procedures, staging, surgical proce-
dures, complications, oncologic treatment, and survival have 
been registered, and since 2005 more than 90% of all Danish 
lung cancer patients have been included in the database. Data 
completeness is determined through comparison with the 
Danish Cancer Registry containing all Danish cancers. The 
values to fulfil the lowest level of each indicator (the thresh-
old) have regularly been revised according to the results of 
reports evaluating the relevant literature.
Organization
Through a continuous process of centralization of clini-
cal departments involved in the treatment of lung cancer in 
Denmark all clinical data are now reported from 28 depart-
ments compared with 90 departments in the early 1990s. Data 
are reported to the database when the diagnostic procedures 
have been completed, or when a specific treatment has been 
initiated and completed.
Operation
Reporting to the database is processed by an Internet-
based closed network with a secured program. Data entry into 
the forms is validated online with regard to data consistency 
and other parameters. Data from the departments are comple-
mented with data from four national databases including data 
on the patients’ personal and demographic status, which are 
retrieved from the Civil Registration System, pathologic infor-
mation from the Pathology Registry, comorbidity data from 
the National Patient Registry, and to ensure a high level of 
data completeness DLCR is compared with the Danish Cancer 
Registry. Figure 1 illustrates the registry structure of DLCR.
Content
Since 2003 DLCR has reported a set of indicators in 
cooperation with the National Indicator Project (Table 1). The 
indicators have over the years largely been unchanged and revised 
only to a minor degree. The indicators are arranged into four top-
ics: survival, waiting times, and stage, and surgical resection rate:
1. Overall survival and survival after surgery are in 
focus in this first indicator. The prognostic factors 
are also listed in Table 1.
2. Danish legislation prescribes standards for maximal 
waiting times to cancer therapy, and these standards 
are reflected in the indicators.
3. Because a correct cTNM stage is absolutely essential 
for the choice of treatment strategy, it is essential that 
all are staged as correctly as possible. An incorrect or 
insufficient cTNM classification can lead to a wrong 
decision in the offering of a potential curative as well 
as a palliative treatment option to patient malprac-
tice. The pTNM stage is considered to be the "true" 
stage and used to validate the correctness of the 
cTNM stage, and the degree of accordance between 
the two is probably the most important indicator of 
the quality of the total diagnostic setup as well as 
for patients being offered surgery and for those being 
offered palliative therapy.
4. Resection rate is a measure of the proportion of a lung 
cancer population that in a given period of time under-
goes curatively indented surgery. Only non–small-cell 
lung cancer (NSCLC) is included in this indicator. 
The rate will relatively be reduced in accordance with 
an increasing quality of the diagnostic setup, resulting 
in a more correct cTNM classification.
The annual reports from DLCR includes a number of 
descriptive analyses such as type of operation (explorative, 
resection, lobectomy, pneumonectomy), type of diagnostic 
procedures used (bronchoscopy, computed tomography [CT], 
positron emission tomography [PET]), rate of complications 
(arrhythmia, infections, air leakage), and proportion of patients 
receiving oncologic treatment with curative intent. These set of 
analyses have been published on a yearly basis and constitute 
an important tool in the national, regional, and local audits.
FIGURE 1.  Danish Lung Cancer Registry (DLCR) system.
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Reporting and the Possibility of 
Surveillance and Intervention
Results are reported in different ways:
Departments, local administrators, and regional qual-
ity offices can check their own data in the online program on 
a day-to-day basis (the database is updated every 24 hours). 
Waiting time, stage distribution, type of operation, 30-day 
mortality, treatment characteristics, and several other topics 
are presented in online reports, showing the current status of 
their activity, and the clinical departments can identify indi-
vidual patients of interest.
These online reports contain data on identifiable indi-
vidual patients and are therefore not public. All other reports 
from DLCR are public, such as:
•  DLCG/DLCR publishes an annual report with focus 
on a limited number of well-defined evidence-based 
indicators. National and regional results are published 
comparing regions and departments. These data are 
followed by comments and recommendations from 
the board of DLCG, which in this context functions 
as a national audit group. Before the publication of 
the annual report a process of local and regional 
audits is performed to identify problems and barriers 
and to propose specific strategies to improve results. 
The annual report also includes detailed informa-
tion on diagnostic procedures, patient characteristics 
(lung functions, smoking, etc.), clinical staging, and 
comorbidity. The surgical procedures, pathological 
stage, and complications are reported as is informa-
tion on oncologic treatment. The data and results are 
reported on national, regional, and department levels 
and an adjusted report is presented to the public. The 
annual report is published in a printed and a digital 
version.
•  Indicator results—without comments—are further-
more reported quarterly to all participating depart-
ments, hospitals, and regions. Data from these reports 
are exported to the regional management information 
systems, and are included in their quality assessments 
and communication to the hospitals and departments. 
Results are together with results from other national 
TABLE 1.  Indicators in the Danish Lung Cancer Registry
Indicator Group No. Indicator Type Threshold, % Time Reference Prognostic Factors Adjustments
I. Survival, overall Ia Rate of patients, surviving  
1 yr from date of diagnosis
Outcome 42 Date of diagnosis Clinical stage,  
Pathology region 
Year of diagnosis 
Operation (yes/no) 
Comorbidity
Age, sex
Ib Rate of patients, surviving  
2 yr from date of diagnosis
Outcome 22
Ic Rate of patients, surviving  
5 yr from date of diagnosis
Outcome 12
II. Survival, after 
surgery
IIa Rate of patients, surviving 30 
days from date of operation
Outcome 97 Date of operation Clinical stage 
Type of operation 
Region 
Year of operation 
Comorbidity
Age, sex
IIb Rate of patients, surviving  
1 yr from date of operation
Outcome 75
IIc Rate of patients, surviving  
2 yr from date of operation
Outcome 65
IId Rate of patients, surviving  
5 yr from date of operation
Outcome 40
III. Waiting times IIIa Rate of patients operated within  
42 days after referral
Structural 85 Date of operation Year of treatment 
Department 
Region
Age, sex
IIIb Rate of patients starting  
oncologic treatment within  
42 days after referral
Structural 85 Date of first 
oncologic 
treatment
IIIc Rate of patients
starting chemo within  
42 days after referral
Structural 85 Date of first chemo
IIId Rate of patients starting 
radiotherapy within  
42 days after referral
Structural 85 Date of first 
radiotherapy
IIIe Rate of patients starting chemo  
and radiotherapy within  
42 days after referral
Structural 85 Date of first chemo 
and radiotherapy
IV. Stage 
classification
IV Rate of patients with  
accordance between cTNM  
and pTNM
Process 80 Date of operation Department  
Region 
Year of operation
Age, sex
V. Resection rate V Rate of patients with NSCLC  
who had a resection
Process 20 Date of operation Region 
Year of diagnosis 
Comorbidity
Age, sex
NSCLC, non–small-cell lung cancer.
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databases used in the accreditation of hospitals in The 
Danish Healthcare Quality Program.
•  DLCG/DLCR publishes ad hoc reports with focus on 
specific issues. For example, did the annual reports 
indicate significant regional differences in treatment 
and survival results? This trigged a report focusing on 
this topic. A report like this gives the opportunity to 
perform comprehensive statistical and epidemiologi-
cal analysis, reinforcing the impact of the report when 
published. Another report has recently analyzed the 
main causes for prolonged waiting times. This analy-
sis will be published separately.
•  Finally, data in DLCR is used in research. Registry-
based research where data in the clinical database and 
other national registries like the Register of Causes 
of Death; the National Health Service Register or 
the population-based Integrated Database for Labour 
Market Research in Statistics Denmark are combined 
and make it possible to investigate relations between 
outcome in lung cancer therapy and socioeconomic 
position or comorbidity. Data are furthermore used in 
clinical research regarding the effects of diagnostic, 
therapeutic, organizational interventions and correla-
tions to data from The National Pathology Registry 
and the Danish Cancer Biobank.
Material
All patients diagnosed in Denmark with primary lung 
cancer are reported to DLCR. A total of 45,424 patients are 
recorded in DLCR since January 1, 2000 through December 
31, 2012. Data registered in the first 2 years are not consid-
ered valid because data completeness was insufficient. DLCR 
started reporting indicators in the National Indicator Project 
in 2003, and in the period January 1, 2003 through December 
31, 2012 38,661 patients have been included. Results reported 
in this article are based on data from patients included in the 
DLCR after January 1, 2003.
Trends in the development in activity and reporting to 
DLCR are shown in Table 2 by first registered treatments and 
year of diagnosis. During 2010 oncologic registration changed 
so that the registration of combined chemo and radiation therapy 
as the initial treatment was no longer possible. The combined 
modalities were counted after the first given modality, and if 
they were given simultaneously this has not been reported.
Pathology data in DLCR originate from the National 
Pathology Registry. The distribution between NSCLC and 
small-cell lung cancer (SCLC) have over the years been con-
stant; 80% is NSCLC, 14% is SCLC, and 6% is without a 
pathologic diagnosis.
Stage distributions are listed in Table 3 grouped after 
year of diagnosis, demonstrating that the cTNM scores—
based on the 2007 TNM classification system—are chang-
ing over years, probably primarily as a result of a higher data 
completeness.
RESULTS
The outcome indicators showing the overall survival 
after 1, 2, and 5 years and the overall survival after surgery 
after 30 days and 1, 2, and 5 years are listed in Table 4.
Table 4 also reports a single result of a process indicator 
of time from referral until start of chemotherapy (maximum 42 
days). The threshold for fulfilling the maximum is 85% and the 
result has improved from approximately 50% to 80%. Figure 2 
shows the results for the five Danish regions, where the vertical 
axis shows the percentage of patients starting treatment within 
the maximum of 42 days, and it is obvious here that differences 
between the regions have diminished over time.
Comparison between the individual results of cTNM 
and pTNM stage or the degree of agreement is another pro-
cess indicator reported in Table 4. Figure 3 shows the results 
for the five Danish regions, where the vertical axis shows the 
percentage of patients with agreement between cTNM and 
pTNM, and it is also here seen that differences between the 
regions have diminished significantly over time.
The last indicator reported in Table 4 is the resection 
rate.
An example of a descriptive analysis from the annual 
report is type of operation shown in Figure 4.
TABLE 2.  Lung Cancer Patients in the Danish Lung Cancer Registry, Registered Treatment; 2003–2012
Year No. Treatment Operation Chemo Radiation
Combined Chemo 
and Radiation Total
2003 1567 (51%) 525 (17%) 319 (10%) 376 (12%) 303 (10%) 3090 (100%)
2004 1261 (37%) 508 (15%) 628 (19%) 614 (18%) 378 (11%) 3389 (100%)
2005 1208 (34%) 594 (17%) 706 (20%) 534 (15%) 482 (14%) 3524 (100%)
2006 1338 (37%) 561 (15%) 796 (22%) 513 (14%) 442 (12%) 3650 (100%)
2007 1273 (33%) 593 (15%) 959 (25%) 520 (13%) 535 (14%) 3880 (100%)
2008 1303 (32%) 635 (15%) 1133 (28%) 523 (13%) 506 (12%) 4100 (100%)
2009 1220 (29%) 652 (16%) 1183 (28%) 586 (14%) 530 (13%) 4171 (100%)
2010 1264 (29%) 720 (17%) 1434 (33%) 701 (16%) 204 (5%) 4323 (100%)
2011 1076 (25%) 738 (17%) 1516 (36%) 933 (22%) 4263 (100%)
2012 1333 (31%) 711 (17%) 1379 (32%) 848 (20%) 4271 (100%)
Total 12,843 (33%) 6237 (16%) 10,053 (26%) 6148 (16%) 3380 (9%) 38,661 (100%)
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DISCUSSION
Theoretical frameworks and methods for quality 
improvement have been described and evolved since the 
1960s.6 Indicator monitoring of outcome, process, and struc-
ture assessments has been established as a valid methodology 
in clinical epidemiology, and the definitions and development 
of clinical indicators have been described.7–9
Until the establishment of DLCG the overall survival 
of lung cancer in Denmark had for decades been 5%. The 
primary aim of the combined efforts of DLCG and DLCR 
TABLE 3.  Stage Distribution among 34,373 Evaluated Patients, cTNM; 2003–2012
Year 0 Ia Ib IIa IIb IIIa IIIb IV Missing Total
2003 11 (0%) 176 (7%) 312 (12%) 10 (0%) 158 (6%) 198 (8%) 511 (20%) 1046 (42%) 91 (4%) 2513 (100%)
2004 15 (1%) 180 (7%) 366 (13%) 10 (0%) 153 (6%) 233 (9%) 519 (19%) 1223 (45%) 26 (1%) 2725 (100%)
2005 21 (1%) 209 (7%) 349 (12%) 13 (0%) 174 (6%) 239 (8%) 607 (21%) 1188 (42%) 47 (2%) 2847 (100%)
2006 9 (0%) 183 (6%) 358 (12%) 12 (0%) 165 (5%) 216 (7%) 684 (23%) 1331 (44%) 51 (2%) 3009 (100%)
2007 13 (0%) 254 (7%) 348 (10%) 28 (1%) 170 (5%) 270 (8%) 749 (22%) 1531 (45%) 54 (2%) 3417 (100%)
2008 21 (1%) 274 (7%) 375 (10%) 35 (1%) 194 (5%) 309 (8%) 743 (20%) 1766 (47%) 56 (1%) 3773 (100%)
2009 16 (0%) 326 (8%) 346 (9%) 19 (0%) 204 (5%) 342 (9%) 684 (18%) 1890 (49%) 22 (1%) 3849 (100%)
2010 16 (0%) 377 (9%) 360 (9%) 33 (1%) 239 (6%) 356 (9%) 696 (17%) 1919 (48%) 30 (1%) 4026 (100%)
2011 17 (0%) 433 (11%) 376 (9%) 28 (1%) 259 (6%) 332 (8%) 719 (17%) 1942 (47%) 13 (0%) 4119 (100%)
2012 19 (0%) 479 (12%) 351 (9%) 25 (1%) 240 (6%) 366 (9%) 646 (16%) 1947 (48%) 22 (1%) 4095 (100%)
Total 158 (0%) 2891 (8%) 3541 (10%) 213 (1%) 1956 (6%) 2861 (8%) 6558 (19%) 15,783 (46%) 412 (1%) 34,373 (100%)
TABLE 4.  Outcome of Result and Structural (No. IIIc) Indicators and Overall Survival after Primary Surgery (Resection)
No. Indicator Threshold 
(%)
2003 
(%)
2004 
(%)
2005 
(%)
2006 
(%)
2007 
(%)
2008 
(%)
2009 
(%)
2010 
(%)
2011 
(%)
2012 
(%)
Ia Patients surviving  
1 yr from date  
of diagnosis
42 36.6 37.4 37.3 37.2 39.3 38.2 38.3 40.2 42.7
Ib Patients surviving  
2 yr from date  
of diagnosis
22 19.8 20.5 20.7 20.9 22.9 21.8 23.0 24.3
Ic Patients surviving  
5 yr from date  
of diagnosis
12 9.8 9.6 10.4 10.5 12.1
IIa Patients surviving  
30 days from  
date of operation
97 93.7 98.4 96.9 96.7 96.8 97.5 97.8 98.0 99.0 99.0
IIb Patients surviving  
1 yr from date of  
operation
75 73.8 76.4 79.7 80.7 83.8 82.2 86.1 85.9 88.6
IIc Patients surviving  
2 yr from date of  
operation
65 60.5 58.9 64.3 67.2 70.6 66.6 73.6 75.5
IId Patients surviving  
5 yr from date of  
operation
40 39.5 38.8 44.5 46.9 48.1
IIIc Rate of patients  
starting chemo  
within 42 days  
after referral
85 62.9 51.1 50.3 56.0 59.8 73.4 72.7 74.7 80.8 82.9
IV Rate of patients  
with accordance  
between cTNM  
and pTNM
85 68.2 70.2 77.0 72.7 79.8 77.6 80.1 83.3 86.4 91.3
V Rate of patients  
with NSCLC  
who had a  
resection
20 18.7 18.9 19.8 20.4 19.8
NSCLC, non–small-cell lung cancer.
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has been to improve survival. The effects of a total popula-
tion may be documented in national registries but are the 
results and the thresholds comparable with international 
standards? Comparing studies based on registry data may 
contain pitfalls, why interpretation of results may be equivo-
cal.10,11 Several of the major European registry reports dem-
onstrate serious differences in data completeness and quality 
of data,12–15 and international comparisons of survival after 
diagnosis of a cancer with a high mortality must therefore 
be performed very cautiously. Data from clinical randomized 
trials and meta-analyses on trials have no major applicability 
in clinical epidemiology. Despite these limitations there has 
been an increasing demand from the health professionals as 
well the health authorities to compare data among registries 
with the purpose of creating national scores and to generate 
hypotheses and new knowledge.16,17 National inventories of 
the character of prospective cohorts do exist, but it should 
always be questioned to what extent the results can be gen-
eralized and transferred to the context of other countries.18–21 
The stage and pathologic classifications are significant prog-
nostic factors in survival, supported by the new revision of 
the stage classification system22,23 and reviews for NSCLC 
and SCLC.24,25
The overall survival of Danish lung cancer patients 
has increased in the documented period (2003–2012). One-
year survival has increased from 36.6% to 42.7%, the 2-year 
survival has increased from 19.8% to 24.3%, and the 5-year 
survival from 9.8% to 12.1%. Improvements in short-term 
survival are significant and must probably be attributed to 
technically improved and more individualized surgical and 
oncologic treatment options and to a significant reduction in 
waiting times because no shift toward a lower-stage distribu-
tion in the overall population has been documented to date. In 
2000 it was estimated that approximately 60% of lung cancer 
patients received treatment compared with 85% in 2012. This 
shift toward a more aggressive treatment strategy is consid-
ered to be caused by several factors among which are a lesser 
fatalistic professional approach to the disease, the emergence 
of scientific data showing positive effect on quality of life 
combined with life-prolonging effects from palliative treat-
ment, better health care system, and better surveillance of 
the implementation of recommended procedures, clinical 
performance, and treatment outcomes. Resection rate has in 
the same period been relatively stable, so patients are now to 
a much higher degree offered oncologic treatment based on 
a more correct stage and pathological type of disease. New 
oncologic treatment modalities have in the observed period 
been introduced. The total number of patients receiving treat-
ment with a curative intent is also relatively stable, but the 
treatment modalities have expanded and improved. Advanced 
new methods like stereotactic radiation therapy, radiofre-
quency ablation, adjuvant chemotherapy, 4D radiation thera-
pies, and others have all been widely available in the latter 
part of the period, and in the last few years targeted therapy, 
including endothelial growth factor receptor-tyrosine kinase 
inhibitor and antivascular endothelial growth factor agents, 
has been in use in an increasing number of patients. In the 
same period improvements in the overall quality of the health 
care system, new follow-up paradigms, and improved rec-
ognition and treatment of recurrence and new primary lung 
cancers also contribute as explanatory factors. The national 
guidelines for the diagnosis and treatment of lung cancer sup-
port the introduction of these new treatment modalities and 
help to ensure that they on a national level are implemented 
fast and uniformly. The public display of regional and depart-
mental results on a yearly basis showing clear differences 
FIGURE 2.  Regional differences, waiting 
time chemotherapy.
FIGURE 3.  Regional differences, accor-
dance between cTNM and pTNM.
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between regions and departments has been an integral and 
important part of the process. Data from DLCR and the 
reporting system deliver feedback to departments and health 
authorities and the subsequent audits, where the involved 
professionals from the departments and the responsible exec-
utives are represented, ensuring that results are discussed and 
that plans of actions are drafted, implemented, and followed. 
The database has also made it possible to analyze these dif-
ferences in further detail. Thus the methods used by DLCG 
and DLCR have contributed to improvement of the quality 
of lung cancer care through monitoring quality indicators, to 
reduction of regional differences significantly, and to security 
and improvement of the national standards in the care and 
management in all phases of the disease.
Thirty-day mortality after surgery is an internationally 
recognized standard for hospital-related mortality, and it is 
agreed that this indicator accurately describes the quality of 
the overall performance pre-, per-, and postoperatively. A 
series of well-performed prospective studies on this subject 
identifies a number of results of this parameter.26–33 Results 
in Denmark have improved significantly (94%–99% in the 
period 2003–2012), and this achievement is to a major extent 
a result of the work with national annual audits among tho-
racic surgeons from the four surgical centers, where all 
peri- and postoperative deaths have been discussed openly, 
analyzed, and identified new risk parameters such as comor-
bidity, performance status, alcohol, and nutritional status. 
Survival after surgery has increased significantly and the 
improvement is also manifested in the increased 5 year sur-
vival from 39.5% to 48.1%. This result may also be con-
ditional to an increasing higher quality of the diagnostic 
setup. Introduction of new technologies as CT, PET-CT, 
endoscopic ultrasound procedures, among others have sig-
nificantly improved the accuracy of the preoperative stag-
ing (cTNM). PET-CT is now being used as a standard in all 
patients referred to surgery. Focus on comorbidity and per-
formance status and an overall improved surgical care have, 
in combination with the more precise preoperative staging, 
resulted in better results.
The influence of diagnostic and treatment delays on 
stage of disease and treatment outcome (survival), respec-
tively, is still a controversial subject. Systematic reviews 
reveal only a limited association between survival and 
delay.34,35 However, latency is a psychological burden for 
the individual patient, and it has been proven that there is 
a correlation between the length of waiting times and the 
extent of psychological stress.36 Several studies show that 
there is no detectable correlation between the length of diag-
nostic workup and the tumor stage in lung cancer. On the 
contrary, several studies have revealed that a quick diagno-
sis is characteristic for advanced cancer, whereas resectable 
cancer often requires lengthier investigations before treat-
ment can be planned.37,38 In the surgical area it is shown that 
latency affects tumor stage,39 but it has not been possible to 
show that the latency affects the survival.40,41 The possibil-
ity of curatively intended radiation therapy of lung cancer 
is affected by tumor size and stage, and studies show that 
stage increase with time to treatment,42 and that this probably 
affects survival.43
DLCR has since 2007 documented a significant 
decrease in time from referral to diagnostics and from diagno-
sis to treatment. Improvements were seen shortly after a very 
direct political statement from the Danish prime minister that 
unnecessary waiting times could not be accepted. DLCR is an 
effective tool documenting changes over time and differences 
between regions and departments, and has through the com-
prehensive use of reports and audits been able to participate in 
and support the development especially during the last 5 years 
of the entire cancer field.
Because staging is essential for an appropriate treat-
ment strategy, any patient who clinically seems to be fit for 
therapy should be staged as correctly as possible. Incorrect 
or inaccurate cTNM classification is as much a problem for 
the individual patient as for health economics. Therefore, the 
degree of concordance between cTNM and pTNM is one of 
the most important quality indicators of the diagnostic setup. 
The effect of a more correct pretreatment staging on overall 
survival is probably marginal, but differences between regions 
and departments in this indicator could explain differences 
in results of treatment. A high number of correctly staged 
patients will increase survival after surgery, but will probably 
not affect overall survival. There have been an increase in sur-
vival of nonsurgical cases in the period, but this is probably 
because of other reasons (better treatment, etc.) than improved 
quality of the diagnostic setup. Both retro- and prospective 
cohort studies comparing cTNM and pTNM have shown 
improved concordance over time, as a result of the intro-
duction of new technology such as PET-CT and endoscopic 
FIGURE 4.  Type of surgical procedures, in five 
time-intervals including the years 2000–2012.
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ultrasound procedures with higher diagnostic accuracy. In the 
first study in this area the agreement was 20% to 58%, depend-
ing on the stage,44 whereas recent studies show concordance 
rates between 33% and 77%.45–47 Routine use of PET-CT in 
the diagnostic process in recent years has further increased 
the overall diagnostic validity, so that up to 80% of patients 
preoperatively are staged correctly.48–51
Danish results are in accordance with these trends 
demonstrated by the results from 2012 in which 91.3% of 
the cTNM registrations were in agreement with the pTNM 
registrations. Geographic comparisons show decreasing dif-
ferences among regions reflecting the impact of our national 
guidelines, equal access to new technologies, and centraliza-
tion of diagnostics on few, highly specialized centers.
The resection rate measures the proportions of the lung 
cancer population that obtain a complete surgical removal of 
the cancer, and the rate normally only refers to NSCLC. The 
indicator is also a measurement of the extent to which the 
health services are able to track patients in an early poten-
tially curable stage of disease and the extent to which the 
surgical departments are able to perform a complete resec-
tion of the tumor.52–54 Normally, a growing resection rate 
results in improved survival data. However, better sensitivity 
of the diagnostic procedures will reduce the resection rate. A 
declining resection rate may lead to increased survival after 
surgery because of stage migration, whereas overall survival 
is not affected. Epidemiological data such as incidence and 
prevalence is important to take into account when changes in 
resection rate and survival are analyzed. Increasing incidence 
because of higher data completeness in the population (the 
denominator) will reduce resection rate and may result in a 
reduced overall survival, because those added to the patient 
population are those who previously were regarded as being 
too ill for a diagnostic workup. Reports of resection rates in 
the literature are subject to great uncertainty. The epidemio-
logical basis behind data is rarely discussed, and estimates 
may be weakened by comparing a noncomplete to a complete 
data set. Often specified rates are reported solely on cyto- or 
histological verified cases.55–57 When including nonverified 
cancers the best series obtains resection rates about 20% for 
NSCLC, and slightly lesser if SCLC is included.
Results in Denmark are reported as the proportion 
of patients with NSCLC being resected (operated patients 
excluding operations where only explorative procedures are 
performed), and shows a minor nonsignificant increase in 
resection rate. In the same period survival after surgery has 
improved significantly as has overall survival. The number 
of stage Ia has increased slightly in the last few years. Why 
that is the case is can be answered speculatively only, but a 
greater awareness in the population toward symptoms of can-
cer and among health professionals in primary and secondary 
care may explain some of the increase. The widespread and 
accepted use of CT scans on broad indications may also con-
tribute to the increase. The rate of explorative procedures has 
declined significantly in recent years because of better diag-
nostic setup (skills and technology).
The type of operation is an example of a descriptive 
analysis in DLCR. As appears from Figure 4 there has been 
a significant movement toward the recommended surgical 
procedures as lobectomy/minor resections and away from 
pneumonectomy and explorative procedures. These findings 
and other observed developments have all improved the total 
quality of patient care.
Despite international data as recently reported58 the 
combined efforts of the DLCG and the DLCR is an example 
of a nationwide quality development system showing that sur-
veillance of the implementation of recommended procedures, 
clinical performance, and treatment outcomes based on spe-
cific quality indicators and national guidelines can contribute 
to improvement in the quality of care. Data quality and com-
pleteness in the DLCR is a very important and confident tool 
for clinicians and other health care stakeholders to document 
the efforts and investments. Over the years discussion issues 
have changed from data quality to interpretation of data, 
which is crucial for progress.
DLCR has chosen an indicator-based quality man-
agement system to evaluate the quality of lung cancer care. 
This method has been evaluated and tested in many different 
health care systems and has been found valid, efficient, and 
usable in facilitating quality improvements.59–62 It is under-
lined in the literature that the variables and their descrip-
tions and thresholds should be evidence based, scientifically 
sound, and a reflection of good clinical practice. If that is the 
case and you have a system of well-organized supervision 
when selecting indicators and performing audits by health 
professionals it is possible to monitor and secure quality 
improvements.63,64 In recent years the traditional indicators 
with focus on professional and organizational quality have 
been expanded, with indicators focusing on patient-experi-
enced qualities. To date, our experience is limited and has 
revealed a number of methodological problems,65,66 but there 
is no doubt that this line of quality measurement will become 
more important and a regular part of the Danish the lung 
cancer quality program.
Further progress in the prognosis in lung cancer 
will primarily originate from achievements in science and 
development of new and better treatments, but meantime 
our health care system constantly must provide the best 
documented treatment, encourage experimental trials, and 
secure availability to all patients regardless of geography 
and social status. The Danish experience shows that a com-
prehensive national quality management system including 
national guidelines, a database with high data quality and 
completeness, frequent reports to the professionals and 
the public, audit and commitment from all stakeholders 
can contribute to improved practice and results and reduce 
regional differences.
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